Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

被引：0
作者：
Yue-qin Wang
Ai-jun Shen
Jing-ya Sun
Xin Wang
Hong-chun Liu
Min-min Zhang
Dan-qi Chen
Bing Xiong
Jing-kang Shen
Mei-yu Geng
Min Zheng
Jian Ding
机构：
[1] China Pharmaceutical University,Department of New Drug Screening Center
[2] Division of Anti-tumor Pharmacology,Department of Thoracic Surgery
[3] Synthetic Organic and Medicinal Chemistry Laboratory,undefined
[4] State Key Laboratory of Drug Research,undefined
[5] Shanghai Institute of Materia Medica,undefined
[6] Chinese Academy of Sciences,undefined
[7] Shanghai Tongren Hospital,undefined
[8] Shanghai Jiao Tong University School of Medicine,undefined
来源：
Acta Pharmacologica Sinica | 2016年 / 37卷
关键词：
non-small cell lung cancer; gefitinib resistance; Hsp90;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1587 / 1596
页数：9
相关论文
共 50 条
  • [31] Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells
    Elsocht, Mathias
    Giron, Philippe
    De Greve, Jacques
    Ballet, Steven
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 79
  • [32] Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation
    Hotta, Katsuyuki
    Tabata, Masahiro
    Kiura, Katsuyuki
    Kozuki, Toshiyuki
    Hisamoto, Akiko
    Katayama, Hideki
    Takigawa, Nagio
    Fujimoto, Nobukazu
    Fujiwara, Keiichi
    Ueoka, Hiroshi
    Tanimoto, Mitsune
    ONCOLOGY REPORTS, 2007, 17 (02) : 313 - 317
  • [33] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [34] MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines
    Zhou, Yong-Ming
    Liu, Juan
    Sun, Wei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (03) : 1391 - 1396
  • [35] For EGFR Mutant Non-Small Cell Lung Cancer, Treatment Sequence Matters?
    An, Ho Jung
    Shin, Yuneyoung
    Hong, Sook Hee
    Kim, Young Kyoon
    Kim, Seung Joon
    Lee, Kyo-Young
    Kang, Jin Hyoung
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S436 - S437
  • [36] The Role of Serine Protease 8 in Mediating Gefitinib Resistance in Non-small Cell Lung Cancer
    Gao, Hai-Jing
    Geng, Xue-Li
    Wang, Ling-Ling
    Zhao, Chun-Nan
    Liang, Zong-Ying
    Xing, En-Hong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2024, 24 (18) : 1339 - 1346
  • [37] CORRELATION ANALYSIS OF EGFR GENE MUTATION FREQUENCY AND RESISTANCE TO GEFITINIB TARGETED THERAPY IN NON-SMALL CELL LUNG CANCER
    Gao, Bo
    Xiao, Wendi
    Shi, Rui
    ACTA MEDICA MEDITERRANEA, 2023, 39 (02): : 509 - 513
  • [38] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [39] Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors
    Ohashi, Yoshimi
    Okamura, Mutsumi
    Katayama, Ryohei
    Fang, Siyang
    Tsutsui, Saki
    Akatsuka, Akinobu
    Shan, Mingde
    Choi, Hyeong-Wook
    Fujita, Naoya
    Yoshimatsu, Kentaro
    Shiina, Isamu
    Yamori, Takao
    Dan, Shingo
    ONCOTARGET, 2018, 9 (02) : 1641 - 1655
  • [40] The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer
    Park, Kang-Seo
    Yang, Hannah
    Choi, Junyoung
    Seo, Seyoung
    Kim, Deokhoon
    Lee, Chang Hoon
    Jeon, Hanwool
    Kim, Sang-We
    Lee, Dae Ho
    CANCER LETTERS, 2017, 406 : 47 - 53
12345